UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 29, 2008
ALLOS THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
Delaware | | 000-29815 | | 54-1655029 |
(State or other jurisdiction | | (Commission | | (IRS Employer |
of incorporation) | | File Number) | | Identification No.) |
| | | | |
11080 CirclePoint Road, Suite 200 | | |
Westminster, Colorado | | 80020 |
(Address of principal executive offices) | | (Zip Code) |
Registrant’s telephone number, including area code: (303) 426-6262
Not applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Section 7 — Regulation FD
Item 7.01 Regulation FD Disclosure.
On May 29, 2008, Allos Therapeutics, Inc. issued a press release announcing the closing of its previously announced public offering of 12,420,000 shares of newly issued common stock at a public offering price of $5.64 per share (which includes 1,620,000 shares purchased by the underwriters pursuant to their exercise in full of their overallotment option). The press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
In accordance with General Instruction B.2. of Form 8-K, the information presented under this Item 7.01 and attached as Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.
Section 9 | | Financial Statements and Exhibits |
| | |
Item 9.01 | | Financial Statements and Exhibits. |
| | |
(d) | | Exhibits. |
| | |
99.1 | | Press Release, dated May 29, 2008, entitled “Allos Therapeutics Announces Closing of Public Common Stock Offering; Underwriters Exercise Overallotment Option to Purchase Additional 1,620,000 Shares.” |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: May 29, 2008
| | ALLOS THERAPEUTICS, INC. |
| | |
| | |
| By: | /s/ Marc H. Graboyes |
| | Marc H. Graboyes |
| Its: | Senior Vice President, General Counsel and Secretary |
3
EXHIBIT INDEX
Exhibit No. | | Description |
99.1 | | Press Release, dated May 29, 2008, entitled “Allos Therapeutics Announces Closing of Public Common Stock Offering; Underwriters Exercise Overallotment Option to Purchase Additional 1,620,000 Shares.” |
4
